Cancer-Associated Fibroblasts Confer Gemcitabine Resistance to Pancreatic Cancer Cells through PTEN-Targeting miRNAs in Exosomes

• Published in: Cancers Vol. 14; no. 11; p. 2812
• Main Authors: Richards, Katherine E, Xiao, Weikun, Hill, Reginald, On Behalf Of The Usc Pancreas Research Team
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 06.06.2022; MDPI
• Subjects: Adenocarcinoma; Cancer therapies; Cell culture; Cell proliferation; Chemoresistance; Chemotherapy; Diagnosis; Drug resistance; Exosomes; Fibroblasts; Gemcitabine; Laboratories; Manufacturers; MicroRNAs; miRNA; miRNAs; Pancreatic cancer; PTEN; PTEN protein; Software; Tumor cells; Tumor microenvironment; Tumor suppressor genes; Tumors; St Louis Missouri; United States > US; Germany; PTEN; fibroblasts; pancreatic cancer; miRNAs; exosomes
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers14112812

Pancreatic ductal adenocarcinoma (PDAC) is currently the third leading cause of cancer-related death in the United States. Even though the poor prognosis of PDAC is often attributed to late diagnosis, patients with an early diagnosis who undergo tumor resection and adjuvant chemotherapy still show tumor recurrence, highlighting a need to develop therapies which can overcome chemoresistance. Chemoresistance has been linked to the high expression of microRNAs (miRs), such as miR-21, within tumor cells. Tumor cells can collect miRs through the uptake of miR-containing lipid extracellular vesicles called exosomes. These exosomes are secreted in high numbers from cancer-associated fibroblasts (CAFs) within the tumor microenvironment during gemcitabine treatment and can contribute to cell proliferation and chemoresistance. Here, we show a novel mechanism in which CAF-derived exosomes may promote proliferation and chemoresistance, in part, through suppression of the tumor suppressor PTEN. We identified five microRNAs: miR-21, miR-181a, miR-221, miR-222, and miR-92a, that significantly increased in number within the CAF exosomes secreted during gemcitabine treatment which target PTEN. Furthermore, we found that CAF exosomes suppressed PTEN expression in vitro and that treatment with the exosome inhibitor GW4869 blocked PTEN suppression in vivo. Collectively, these findings highlight a mechanism through which the PTEN expression loss, often seen in PDAC, may be attained and lend support to investigations into the use of exosome inhibitors as potential therapeutics to improve the effectiveness of chemotherapy.